Skip to content
Menu

Cogent Biosciences, Inc. COGT

Full chart Compare
Set alert

Price alert · COGT

All alert types
26.72 USD -1.02 (-3.70%)

Regular-session close

27.26 +0.55 +2.04%

After hours · Nov 20, 5:14 PM ET

26.62 Day range 27.83
26.36 52-week range 43.73
YTD
-24.79%
1 year
-23.01%

5D -0.36 (-1.25%)

272829FriMonTueWedThu28.45
Market cap
4.65B
EPS (ttm)
-2.26
Shares out
173.99M
Forward P/E
-21.07
YTD return
-24.79%
1-year return
-23.01%
50-day average
30.84
200-day average
35.12
Enterprise value
4.35B
Price / book
10.30
Volume
2.12M
Avg volume
2.07M
Open
27.26
Previous close
27.74
Day's range
26.62 – 27.83
52-week range
26.36 – 43.73
Beta
0.34
Analysts
Strong Buy
Price target
55.82 (+108.9%)
Earnings date
Feb 16, 2027

Key statistics

Free cash flow
-191.62M
Total cash
791.13M
Total debt
244.22M
Return on equity
-99.59%
Short % of float
10.07%

Fundamental scorecard

3 of 25 checks passed on COGT’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
COGT Revenue — quarterly 0
COGT Net income — quarterly -111.43M
COGT EPS — quarterly -0.59

Earnings

COGT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 30, 2026-0.63———
Nov 5, 2026Sep 30, 2026-0.56362-0.59-0.03-4.68%
Aug 10, 2026Jun 30, 2026-0.55497-0.52+0.03+6.30%
May 5, 2026Mar 31, 2026-0.53-0.530.000.00%
Feb 17, 2026Dec 31, 2025-0.51-0.55-0.04-7.84%
Nov 7, 2025Sep 30, 2025-0.54-0.50+0.04+7.41%

Upgrades / downgrades

COGT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026HC Wainwright & Co.mainBuyBuy
Sep 16, 2026WedbushreitOutperformOutperform
Sep 15, 2026HC Wainwright & Co.reitBuyBuy
Aug 17, 2026Piper SandlermainOverweightOverweight
Aug 12, 2026GuggenheimmainBuyBuy
May 29, 2026WedbushreitOutperformOutperform

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on COGT — it syncs with the Stock Master app.

Insider holders

COGT insider holders
InsiderRelationLatest transactionDateShares held
FAIRMOUNT FUNDS MANAGEMENT LLCDirectorSaleJan 21, 20260
GREEN JOHN LChief Financial OfficerSaleDec 25, 2025131,834
KEARNS EVAN D J.D.OfficerSaleDec 25, 2025109,398
MORRIS ARLENE M.DirectorConversion of Exercise of derivative securityAug 26, 20260
PINNOW COLEOfficerStock Award(Grant)Dec 16, 2025216,650
ROBBINS ANDREW R.Chief Executive OfficerStock GiftMay 18, 2026657,503

Institution ownership

COGT institution ownership
Holder% heldSharesValueReported
FMR, LLC15.43%26,852,012717.35MSep 29, 2026
Blackrock Inc.9.90%17,228,842460.27MSep 29, 2026
Vanguard Portfolio Management LLC4.67%8,131,026217.22MSep 29, 2026
State Street Corporation4.47%7,770,149207.58MSep 29, 2026
Vanguard Capital Management LLC4.28%7,448,057198.97MSep 29, 2026
Janus Henderson Group Ltd.4.27%7,432,956198.57MSep 29, 2026

Fund ownership

COGT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.96%5,156,952137.77MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.48%4,316,858115.32MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.24%3,900,938104.21MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.14%3,724,03399.49MJun 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund1.44%2,509,15767.03MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.36%2,358,21263.00MJun 29, 2026